AUROBINDO

PRESS RELEASE

23rd February 2011

The Cephalosporin facility, Unit VI of Aurobindo Pharma Limited (APL) located at Survey, No. 329/39 & 329/47, Chitkul Village, Hyderabad, Andhra Pradesh, India has been audited by USFDA in the month of December 2010. The Company has sent the compliance report to USFDA, which is under review. Subsequent to the audit findings USFDA has imposed an import alert on their website for detention on APL Unit VI products. On learning the same, APL is trying to establish contact with USFDA to understand the correct interpretation of such an alert on whether it relates only to sterile products and/or oral products manufactured at Unit VI. APL present thinking is to ascertain the scope of this Import ban alert and request USFDA for a face to face meeting at the earliest and present the facts with a view to comply with all the USFDA regulations and bring back the Unit VI to active operations for US market at the earliest. Until then , it will impact any further shipment from unit VI to US market.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:
Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com